SCHEMBL6071993

SCHEMBL6071993

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1cccc(NC(=O)C(C)(C)NC(=O)C(F)(F)F)c1)=NC(C)(C)C2

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.35
KMT2A Q03164 3/20 0.33
POLB P06746 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 3/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
TP53 P04637 1/20 0.31
JAK3 P52333 1/20 0.31
TSHR P16473 1/20 0.31
HBB P68871 1/20 0.31
KCNK3 O14649 1/20 0.31
KCNK9 Q9NPC2 1/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072505 0.94 IRAK4 (0.36) IRAK4KMT2APOLBLMNAMAPT
Hydrochloric Acid SCHEMBL5784199 0.91 CYP1A2 (0.33) KMT2ALMNAMAPTTP53HTR2A
SCHEMBL6072152 0.89 POLB (0.34) IRAK4KMT2APOLBLMNAMAPT
SCHEMBL5783860 0.85 CYP1A2 (0.39) KMT2ALMNAMAPTTP53HTR2A
SCHEMBL6072366 0.85 LMNA (0.36) IRAK4KMT2APOLBLMNAMAPT
SCHEMBL5787624 0.84 CYP1A2 (0.37) KMT2AMAPTTP53HTR2AHTR2C
SCHEMBL5786654 0.84 LMNA (0.39) KMT2APOLBLMNAMAPTALDH1A1
SCHEMBL5783309 0.83 LMNA (0.38) IRAK4KMT2APOLBLMNAMAPT
SCHEMBL5787539 0.81 LMNA (0.37) KMT2APOLBLMNAMAPTALDH1A1
SCHEMBL6072391 0.81 KMT2A (0.41) KMT2APOLBLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A IRAK4 1857/4885KMT2A 878/4885POLB 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.